Top

Diabetologia

Published in:

Open Access 01-10-2009 | Article

Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes

Authors: A. Rune, M. E. Osler, T. Fritz, J. R. Zierath

Published in: Diabetologia | Issue 10/2009

Abstract

Aims/hypothesis

Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is involved in cellular stress responses linked to obesity and type 2 diabetes. We determined the role of SNARK in response to metabolic stress and insulin action on glucose and lipid metabolism in skeletal muscle.

Methods

Vastus lateralis skeletal muscle biopsies were obtained from normal glucose tolerant (n = 35) and type 2 diabetic (n = 31) men and women for SNARK expression studies. Primary myotube cultures were derived from biopsies obtained from normal glucose tolerant individuals for metabolic studies.

Results

SNARK (also known as NUAK2) mRNA expression was unaltered between normal glucose tolerant individuals and type 2 diabetic patients. SNARK expression was increased in skeletal muscle from obese (BMI >31 kg/m²) normal glucose tolerant individuals and type 2 diabetic patients (1.4- and 1.4-fold, respectively, p < 0.05) vs overweight (BMI <28 kg/m²) normal glucose tolerant individuals and type 2 diabetic patients. SNARK mRNA was increased in myotubes exposed to palmitate (12-fold; p < 0.01), or TNF-α (25-fold, p < 0.05), but not to oleate, glucose or IL-6, whereas expression of the AMP-activated protein kinase α2 subunit was unaltered. Small interfering (si)RNA against SNARK reduced mRNA and protein in myotubes by 61% and 60%, respectively (p < 0.05). SNARK siRNA was without effect on basal or insulin-stimulated glucose uptake or lipid oxidation, and insufficient to rescue TNF-α- or palmitate-induced insulin resistance.

Conclusions/interpretation

Skeletal muscle SNARK expression is increased in human obesity, and in response to metabolic stressors, but not type 2 diabetes. Partial SNARK depletion failed to modify either glucose or lipid metabolism, or protect against TNF-α- or palmitate-induced insulin resistance in primary human myotubes.

Long YC, Zierath JR (2008) Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab 295:E545–E552PubMedCrossRef

Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 32(Suppl 4):S7–S12CrossRef

Lizcano JM, Goransson O, Toth R et al (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833–843PubMedCrossRef

Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934PubMedCrossRef

Al-Hakim AK, Goransson O, Deak M et al (2005) 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. J Cell Sci 118:5661–5673PubMedCrossRef

Sakamoto K, Goransson O, Hardie DG, Alessi DR (2004) Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 287:E310–E317PubMedCrossRef

Koh HJ, Arnolds DE, Fujii N et al (2006) Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol 26:8217–8227PubMedCrossRef

Tsuchihara K, Ogura T, Fujioka R et al (2008) Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci 99:677–682PubMedCrossRef

Rosen CF, Poon R, Drucker DJ (1995) UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes. Am J Physiol 268:C846–C855PubMed

10.

Lefebvre DL, Bai Y, Shahmolky N et al (2001) Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. Biochem J 355:297–305PubMedCrossRef

11.

Lefebvre DL, Rosen CF (2005) Regulation of SNARK activity in response to cellular stresses. Biochim Biophys Acta 1724:71–85PubMed

12.

Egan B, Zierath JR (2009) Hunting for the SNARK in metabolic disease. Am J Physiol Endocrinol Metab 296:E969–E972PubMedCrossRef

13.

Kuga W, Tsuchihara K, Ogura T et al (2008) Nuclear localization of SNARK; its impact on gene expression. Biochem Biophys Res Commun 377:1062–1066PubMedCrossRef

14.

Al-Khalili L, Kramer D, Wretenberg P, Krook A (2004) Human skeletal muscle cell differentiation is associated with changes in myogenic markers and enhanced insulin-mediated MAPK and PKB phosphorylation. Acta Physiol Scand 180:395–403PubMedCrossRef

15.

Bouzakri K, Zierath JR (2007) MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 282:7783–7789PubMedCrossRef

16.

Al-Khalili L, Chibalin AV, Kannisto K et al (2003) Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. Cell Mol Life Sci 60:991–998PubMed

17.

Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57:2066–2073PubMedCrossRef

18.

Sabin MA, Stewart CE, Crowne EC et al (2007) Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid. J Cell Physiol 211:244–252PubMedCrossRef

19.

Ichinoseki-Sekine N, Naito H, Tsuchihara K et al (2009) Provision of a voluntary exercise environment enhances running activity and prevents obesity in Snark-deficient mice. Am J Physiol Endocrinol Metab 296:E1013–E1021PubMedCrossRef

20.

Sakamoto K, McCarthy A, Smith D et al (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24:1810–1820PubMedCrossRef

21.

Mu J, Brozinick JT Jr, Valladares O, Bucan M, Birnbaum MJ (2001) A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085–1094PubMedCrossRef

22.

Jorgensen SB, Viollet B, Andreelli F et al (2004) Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 279:1070–1079PubMedCrossRef

23.

Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375PubMedCrossRef

24.

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed

25.

Legembre P, Schickel R, Barnhart BC, Peter ME (2004) Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem 279:46742–46747PubMedCrossRef

Title: Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes
Authors: A. Rune
M. E. Osler
T. Fritz
J. R. Zierath
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1465-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 10/2009

Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort

Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans

Circulating β-carotene levels and type 2 diabetes—cause or effect?

Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study

Lise G. Heding, 1936–2008

Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials